# Min Yan

**Type:** Researchers  
**Canonical URL:** https://scholariq.org/researchers/min-yan/

## Facts

| Field | Value |
| --- | --- |
| Citations | 20,529 |
| Field | HER2/EGFR in Cancer Research |
| h-index | 68 |
| i10-index | 270 |
| Last Known Institution | Zhengzhou University |
| OpenAlex ID | https://openalex.org/A5056443419 |
| ORCID iD | https://orcid.org/0000-0002-3911-748X |
| Works | 717 |

## Researcher papers

- [Primary results from IMpassion131, a double-blind, placebo-controlled, randomised phase III trial of first-line paclitaxel with or without atezolizumab for unresectable locally advanced/metastatic triple-negative breast cancer](https://scholariq.org/papers/primary-results-from-impassion131-a-double-blind-placebo-controlled-randomised/)
- [Pyrotinib plus capecitabine versus lapatinib plus capecitabine for the treatment of HER2-positive metastatic breast cancer (PHOEBE): a multicentre, open-label, randomised, controlled, phase 3 trial](https://scholariq.org/papers/pyrotinib-plus-capecitabine-versus-lapatinib-plus-capecitabine-for-the-treatment/)

## Researcher topics

- [HER2/EGFR in Cancer Research](https://scholariq.org/topics/her2-egfr-in-cancer-research/)
- [Advanced Breast Cancer Therapies](https://scholariq.org/topics/advanced-breast-cancer-therapies/)
- [Gastric Cancer Management and Outcomes](https://scholariq.org/topics/gastric-cancer-management-and-outcomes/)
- [Cancer Treatment and Pharmacology](https://scholariq.org/topics/cancer-treatment-and-pharmacology/)
- [Cancer, Hypoxia, and Metabolism](https://scholariq.org/topics/cancer-hypoxia-and-metabolism/)

## Researcher university

- [Zhengzhou University](https://scholariq.org/institutions/zhengzhou-university/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.